Merck has begun its tender offer for Terns Pharmaceuticals. Read what the deal could change for metabolic drug competition and pipeline strategy.
Caliway’s CBL-514 heads to ADA 2026 with tirzepatide combination data. Read what this could change in obesity treatment strategy.
TIXiMED reports preclinical data showing oral TIX100 may prevent weight regain after GLP-1 therapy. Discover what this could mean for obesity treatment.
ARPA-H backs Seaport Therapeutics’ GlyphCele program targeting gut lymphatics in metabolic disease and pancreatic cancer. Read the analysis.
Can oral ribupatide reshape obesity treatment economics and adoption? Explore what Phase 2 data mean for GLP-1 pill strategies.
Ascletis starts U.S. Phase II trial of ASC30 in type 2 diabetes. Find out what this oral GLP-1R agonist could mean for the future of metabolic therapies.
Innovent Biologics, Inc. has achieved a landmark moment in China’s clinical research trajectory with the back-to-back publication of two Phase 3 clinical trials of mazdutide, a dual GCG/GLP-1 receptor agonist, in Nature as Accelerated Article Previews. These studies, known as DREAMS-1 and DREAMS-2, evaluated the drug as monotherapy and as an add-on therapy in Chinese […]
OrsoBio’s TLC-6740 combo data hints at a new way to break GLP-1 plateaus. Read what this could change in obesity drug development.
Zealand Pharma A/S and OTR Therapeutics have entered a multi-program strategic collaboration and licensing agreement to develop novel oral small-molecule therapies for metabolic diseases. The deal includes an initial payment of USD 20 million to OTR Therapeutics, which could increase to USD 30 million under predefined conditions. Total consideration may reach approximately USD 2.5 billion, […]